The National Organization for Rare Disorders (NORD) has expressed its profound sorrow following the passing of former U.S. Senator Nancy Kassebaum Baker, a Republican who represented Kansas in the United States Senate and whose visionary leadership fundamentally altered the course of history for millions of individuals living with rare diseases.
More than four decades ago, during an era when individuals diagnosed with rare medical conditions faced a stark landscape characterized by virtually no treatment options and little to no influence over the healthcare and regulatory systems intended to serve them, Senator Kassebaum chose to listen. Her entry into the rare disease legislative sphere began not through political maneuvering or bureaucratic initiative, but through a direct, personal encounter with a Kansas family grappling with the devastating realities of Huntington’s disease.
The pivotal moment unfolded when a husband and wife from Kansas traveled to Washington to make an impassioned plea to their senator. The wife was living with Huntington’s disease, a progressive brain disorder that causes uncontrolled movements, emotional problems, and loss of cognition. Together, the couple explained to Senator Kassebaum that families facing rare conditions urgently needed Congress to take decisive action to encourage the development of specialized medications. When the senator asked what she could do to help, they delivered a direct and compelling request: the fledgling Orphan Drug Act needed a committed champion in the United States Senate.
Demonstrating the responsiveness that would hallmark her distinguished career in public service, Senator Kassebaum answered their call without hesitation. Within days of the meeting, she mobilized her congressional staff, took up the mantle, and officially introduced the legislation in the Senate. Their remarkable story has since endured as a powerful testament to what becomes possible when the voice of a single rare disease family reaches a leader possessing the empathy and resolve to act.
The resulting legislation, the Orphan Drug Act, was officially signed into law in 1983, fundamentally transforming the therapeutic landscape for people living with rare conditions. Before the enactment of the law, pharmaceutical companies had little financial incentive to research, develop, and market treatments for medical conditions affecting small patient populations, as the high costs of development could not be recouped. The Orphan Drug Act changed this dynamic by providing crucial financial incentives, tax credits, and market exclusivity provisions for the development of treatments targeting rare conditions. In doing so, it established a durable foundation upon which generations of patients, advocates, academic researchers, government regulators, policymakers, and industry leaders have continued to build over the ensuing decades.
Senator Kassebaum’s close relationship with the rare disease advocacy community was woven directly into the foundational history of NORD itself. The dedicated patient coalition that mobilized to advocate for the passage of the Orphan Drug Act formally incorporated as NORD shortly after the law successfully passed through Congress. This milestone marked the beginning of a powerful, collaborative partnership between patients and policymakers that remains vital to the rare disease community today. Recognizing this historic contribution, NORD proudly honored Senator Kassebaum with its Leadership in Public Policy Award in 2013, as the organization commemorated the thirtieth anniversaries of both the Orphan Drug Act and its own founding.
Reflecting on the fierce legislative battle required to enact the law, Abbey S. Meyers, the founder of NORD, recalled the tenacity of the late senator. Senator Kassebaum fought like a tiger to get the Orphan Drug Act through the Senate, Meyers noted, adding that having been present during those legislative battles, she understood firsthand how arduous the fight truly was. At a historical juncture when people afflicted with rare diseases were frequently treated as though their lives did not matter simply because there were too few of them, Senator Kassebaum clearly understood what was at stake. Looking back more than forty years later at the countless lives that have been saved, extended, and profoundly changed because the legislation became law, Meyers emphasized that this represents an extraordinary legacy which the rare disease community must never forget.
Pamela K. Gavin, the Chief Executive Officer of NORD, also shared reflections on the profound and lasting impact of the senator’s career. Noting that she did not have the personal privilege of knowing Senator Kassebaum, Gavin expressed the deep privilege she feels today in leading an organization and serving a community that was so profoundly shaped by the senator’s legislative vision. When patients and families courageously stepped forward to explain that the existing healthcare and economic systems were failing them, Senator Kassebaum listened attentively and then translated those concerns into concrete action, helping to transform individual voices into lasting systemic change.
Gavin further underscored that the Orphan Drug Act accomplished far more than merely altering the economic calculations surrounding the development of treatments for small patient populations. Crucially, the legislation helped set in motion a comprehensive framework for rare disease research, scientific innovation, and cross-sector collaboration that has steadily grown, strengthened, and expanded over more than four decades. The medical and therapeutic progress witnessed across the rare disease ecosystem today stands, in significant part, upon the sturdy foundation that Senator Kassebaum helped construct. On behalf of NORD and the millions of Americans across the country living with rare diseases, Gavin extended deepest condolences to the family of Senator Kassebaum, alongside enduring gratitude for a lifetime of dedicated public service, noting that her legacy continues to live on in every medical advance made possible by the framework she helped create.
Throughout a distinguished career defined by public service and bipartisan engagement, Senator Kassebaum earned a reputation as a thoughtful, diligent legislator. For the millions of Americans navigating the challenges of rare diseases, however, she will forever be remembered as a leader who took the time to listen, recognized that individuals afflicted with rare medical conditions were no less deserving of care simply because they were few in number, and successfully translated those fundamental principles into enduring, life-changing public policy.
